Managing Toxicities Following BCMA-Directed Immunotherapy for Myeloma

EP: 1.Reviewing the Approval Process of Teclistamab in Multiple Myeloma

EP: 2.Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride

EP: 3.ASH 2023: The Most Relevant Multiple Myeloma Data Presented

EP: 4.ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma

EP: 5.Ide-Cel Receives Favorable ODAC Vote for R/R Multiple Myeloma

EP: 6.FDA Approves Ide-Cel in Previously Treated Multiple Myeloma

EP: 7.FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy

EP: 8.Managing Cranial Nerve Impairment in Multiple Myeloma Following Cilta-cel

EP: 9.APPs Focus on Education of Talquetamab Use and Administration in Multiple Myeloma

EP: 10.Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma

EP: 11.Daratumumab Retreatment Yields Sustained Response in R/R Multiple Myeloma

EP: 12.Step-Up Teclistamab Dosing Produces Responses in R/R Multiple Myeloma

EP: 13.Building On Outcomes With Isatuximab in Newly Diagnosed Myeloma

EP: 14.Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

EP: 15.Leveraging CAR T-Cell Therapy Advancements in R/R Multiple Myeloma

EP: 16.FDA Approves Subcutaneous Daratumumab Regimen in Newly Diagnosed Multiple Myeloma

EP: 17.Bispecific Antibodies Are Taking the Multiple Myeloma World by Storm

EP: 18.MRD May Predict Improved Outcomes in Multiple Myeloma

EP: 19.Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

EP: 20.Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma

EP: 21.Exploring GPRC5D as an Important Target for Multiple Myeloma

EP: 22.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma

EP: 23.Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma

EP: 24.Optimizing AE Management Post CAR T-Cell Therapy in Multiple Myeloma

EP: 25.Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma

EP: 26.Daratumumab Combo Yields MRD-Negative Status in Transplant-Ineligible NDMM

EP: 27.Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

Now Viewing

EP: 28.Managing Toxicities Following BCMA-Directed Immunotherapy for Myeloma

EP: 29.Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma

EP: 30.Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

EP: 31.Multiple Myeloma Experts Face Off on Sequencing Therapy Options

EP: 32.D-VRd Regimen Sustains MRD Response In Newly Diagnosed Multiple Myeloma Subgroup

EP: 33.Maintenance Teclistamab Yields Preliminary Activity in NDMM

EP: 34.General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

EP: 35.Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma

EP: 36.Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM

EP: 37.Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma

EP: 38.Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma

EP: 39.CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma

EP: 40.Appropriately De-Escalating Talquetamab to Monthly Dosing in Multiple Myeloma

BCMA, which is present in both myeloma cells and healthy cells, could suppress immune cells, making patients more susceptible to potentially fatal severe infections, according to James R. Berenson, MD.

CancerNetwork® spoke with Berenson, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research, and private practitioner in West Hollywood, California, about how BCMA levels impact response to direct immune therapies and toxicities following treatment with BCMA-directed bispecific antibodies.

Berenson began by outlining a correlation between higher levels of BCMA and lower responses, emphasizing a generally more aggressive tumor state and larger tumor burden in patients with higher BCMA levels. He then expressed that treatment with BCMA-directed therapies may elicit toxicity.

The first toxicity he outlined was cytokine release syndrome (CRS), which could be fatal but typically occurs the first few days following treatment. Common symptoms include fevers and aches, among others, with severe instances mitigated with steroids. Berenson then explained that interleukin-6, an antibody target, may be a cause of CRS, and that treatment with tocilizumab (Actemra) may help to treat the toxicity.

Furthermore, Berenson explained that immune effector cell-associated neurotoxicity syndrome (ICANS) is another toxicity that may occur following treatment with BCMA-directed immune therapies. Although uncommon, Berenson explained that symptoms can occur within days and be severe, which may include seizures, Guillain-Barré syndrome, headaches, numbness, and weakness, among others.

Transcript:

in terms of patients who are getting BCMA-directed immune therapies––T cells that are called bispecific antibodies––it was thought that higher levels of BCMA may mean you are more likely to respond. It turns out, that is not the case. Consistent with all our other data, it seems that higher levels, whether it is a BCMA-directed therapy or non–BCMA-directed therapy, make it less likely you are going to respond to that treatment. That is [likely] a result of the amount of tumor that you have on board and its aggressive state, because we know that there is more of it on more aggressive myeloma. If you have worse myeloma, as well, you may have a larger tumor burden in your body than the patient who does not have that much myeloma. Therefore, you have more BCMA on the cells, and then more BCMA shed in the blood.

BCMA-directed therapies are highly effective but can be highly toxic. Early on, patients can experience an immune, overripe reaction, similar to what happens in patients, for example, who have COVID-19 infections, in which the immune system comes out unregulated. We call that cytokine release syndrome [CRS]. It can be fierce. It could be fatal. [Patients] often have fevers, do not feel well, and have aches––they can have all sorts of problems, but that usually only occurs the first few days. If it is bad, it can be mitigated with steroids.

An antibody target is one of the factors that is thought to be the culprit, and that is called interleukin-6. There is a drug called [tocilizumab; Actemra] that can help with that. It does not occur that often, but you certainly have to be aware of it. Patients are supposed to be hospitalized the first few days in case they get into trouble, [then] they can be acted upon immediately.

The other major problem they get early is called immune effector cell-associated neurotoxicity syndrome [ICANS], a neurological syndrome. [This can include] seizures, Guillain-Barré syndrome, headaches, numbness, [or] weakness. These symptoms can be severe, but again, uncommon. It usually occurs in the first few days and then goes away. There are other neurological symptoms that can occur outside of ICANS as well.

Now, as the patient traverses further, the BCMA, unfortunately, is not only present on the myeloma cells, but normal immune cells. This is a thorough take out of your immune cells, whether they are malignant or [benign] plasma cells. Thus, you are like the emperor with no clothes; you do not have an immune system. These patients get into trouble with severe infections. They can be fatal.